Terms & Conditions

All policies and Terms of Registration are adopted in consideration of, and in the best interest of, conference attendees, exhibitors, event co-sponsors and the conference venue. As a condition of registration, you agree to all of the terms and policies contained herein, as well as all other reasonable policies promulgated by the Conference Organisers.

1. Registration Processing

Registrations received without full payment prior to the deadline for Early bird pricing will not automatically qualify for the discounted rate. The applicable rate will be assessed at the time full payment is received. Note: Registrations received without payment will not be processed until payment is received.

2. Transferring of Registration

Delegates who are unable to attend the conference may send another individual of their choice, provided we receive the transferee’s registration application at least three (3) weeks prior to the start of the conference. Approval of this transfer is at the discretion of the Conference Organisers.

3. Registration Cancellations/Refunds

All registration cancellations must be received in writing five weeks before the first day of the conference (or delivered by e-mail to the address provided in the Contact Us section below). A refund of the conference fee, minus a $75 administrative fee, will be given for cancellations that are received in a timely manner. Refund requests received after this date will be considered on an individual basis.

4. Event Cancellation

The Conference Organisers reserve the right to cancel this event without liability, and the total amount of any and all liability of the organisers will be limited to a refund of any registration fees. Any fees associated with cancellation of travel or housing reservations is the exclusive responsibility of conference attendees.

5. Coronavirus (COVID-19)

We are committed to following all public health directives from Safe Work Australia and the NSW Government in relation to hosting our event. Conference attendees are required to comply with all directives in force at the time of the conference.

The NSW Government is continually monitoring the status of COVID-19 in the community and restrictions relating to public gatherings and travel are constantly changing. For the latest information and advice see the following websites:

Changing COVID-19 public health advice may impact on our in-person program, which we currently have scheduled for 12 – 14 September 2022. If restrictions are put into place that prevent us from running face-to-face activities, the conference organisers reserve the right to change the conference program accordingly, including moving the entire program online for virtual participation only. In this case delegates will be advised of the refund policy which will be put in place at the time the decision is made.

If you are travelling to Sydney (NSW) from another Australian state or territory to attend the conference in-person, please regularly check nsw.gov.au for the latest information about traveling to and from NSW. Overseas attendees should consult the Australian Border Force and the Australian Government Department of Health’s Coronavirus (COVID-19) advice for international travellers

6. Speaker Substitution

The Conference Organisers reserve the right to substitute an equally qualified speaker in case of an emergency or cancellation. The Conference Organisers make no endorsements of any presentation or product and have no duty of due diligence with respect to presenters, exhibitors, or sponsors.

7. Identification

Attendees are asked to present their Registration Confirmation document at registration in order to collect registration materials.

8. Name Badges

Delegates are reminded that it is important to wear your badge at all times. This allows you uncomplicated access to conference events. However, for security reasons, please remember to remove your badge when you are outside the conference events and venues.

9. Photographs/Videos

Photographs, video and audio recordings will be taken during the Conference and associated events to produce a record of the Conference. Some content will be made available to those who cannot attend.

You hereby grant the Conference Organisers an irrevocable, worldwide, royaltyfree, fully-paid up license to reproduce, copy, display, perform, or otherwise use any photos, videos or audio recordings taken of you by the Conference Organisers or their agents for promotional use (i.e. brochures, association publications, web-based media – blogs, websites, e-newsletters). You hereby release and hold harmless the Conference Organisers and their agents and assigns from all claims, demands, causes of action and liability related to said use of the material. Please contact us in advance of the conference if this poses a problem for you.

10. Delegate Information

The Conference Organisers may provide a list of delegate contact details to the conference sponsors. Should you not wish your details to be provided to such conference sponsors, please advise us using one of the means provided in the Contact Us section below. The delegate list will not be made available to any parties other than specified conference sponsors, and will not be traded or sold in any form.

11. Conference Etiquette

To make the conference experience an enjoyable event for all attendees, we ask that you please keep the following in mind:

  • As a courtesy to our speakers, please refrain from using mobile phones during presentations, unless you are participating in live polling via a conference app.
  • Participants of this conference are in attendance to learn. Therefore, in consideration of all attendees we ask that you please hold any conversations outside session rooms.

12. Smoking

This event is being held at a non-smoking venue. Designated smoking areas are available, please contact venue staff for details.

13. Marketing Activities

Attendees are prohibited from distributing materials or otherwise marketing themselves or businesses at the conference unless they are a paid exhibitor or sponsor. This applies to all areas of the conference venue, including the exhibition areas, session rooms, and break areas. Paid Sponsors and Exhibitors may exhibit in the exhibition area, and must limit marketing activities to their designated area (confines of their booth) or other paid sponsorship event.

14. Consumption of Alcohol

The Conference Organisers expressly disclaim any liability arising out of attendee’s consumption of alcoholic beverages at the conference or associated events. Certain conference events, receptions and parties will serve alcoholic beverages, and conference participants are responsible for their own well being. Persons under the age of 18 or those deemed to be intoxicated will be denied alcoholic beverages. The Conference Organisers expressly disclaim liability for any acts or omissions of attendees resulting from excessive drinking, recklessness or negligence on the part of any conference participant(s).

15. Limitation of Liability

The Conference Organisers expressly disclaim liability for acts or omissions of the organisers and for third parties including facilities, suppliers, and exhibitors in conjunction with the event, or for the safety of any attendee while in transit to or from this event. The Conference Organisers shall not be liable for any delays, interruption of services, or failure in performance resulting directly or indirectly from any cause or circumstance beyond the reasonable control of the organisers. This includes but is not limited to, failure of transportation, weather, accidents, fires, electrical failures, strikes, labour disputes, postal delays, explosions, government orders or regulations, war, terrorism, or acts of God. Attendees who purchase non-refundable airline tickets do so at their own risk.

Attendees/Exhibitors/Sponsors at the conference agree to indemnify, defend and hold harmless the Conference Organisers and their officers, directors, and agents against all claims arising out of actions or omissions of Attendees/Exhibitors/ Sponsors at or in connection with the Arts Activated 2019 event except for the Conference Organisers own gross negligence or willful misconduct. The Conference Organisers agree to indemnify and hold harmless Attendees/Exhibitors/Sponsors against all claims arising out of the acts of omissions of the conference Organisers and their officers, directors, and agents in connection with the Arts Activated 2019 event except for Attendee’s/Exhibitor’s/Sponsor’s own gross negligence or willful misconduct.

16. How To Contact Us

If you have a query in relation to this Privacy Policy or you would like to notify Small Talk Events that you no longer wish to receive marketing material from us, access or correct your Personal Information or to make a complaint about Small Talk Events’ handling of your Personal Information, please contact Small Talk Events as follows:

Small Talk Events
PO Box 490
West Ryde NSW 1685
T 0422 116 849

Conference Organisers: The Australasian Wound and Tissue Repair Society, and Small Talk Events Pty Ltd.

Simon Cool
Director of the UQ Advanced Cell Therapy Manufacturing Initiative, and Director of Research in the School of Chemical Engineering at the University of Queensland

Professor Cool began his scientific career at the University of Queensland over 20 years ago. He received his BSc (hons) and PhD degrees from the University of Queensland, where he subsequently held a faculty position in the School of Biomedical Sciences. His areas of study have included age-related changes in the structure of bone and teeth and the extracellular matrix compartment of skeletal tissue that guide stem cell behaviour and wound repair. Professor Cool was invited to join the Institute of Molecular and Cell Biology (IMCB), A*STAR, Singapore in 2003 as a Principal Investigator. He then joined A*STAR’s Institute of Medical Biology (IMB) in 2008, shortly after its inception, to further his research in regenerative medicine, serving as Senior Principal Investigator of the Glycotherapeutics Group. In October 2020, Professor Cool re-joined the Institute of Molecular and Cell Biology (IMCB) as a Research Director, Glycotherapeutics, where he focused on developing novel glycosaminoglycan biomolecules that enhance wound repair and control adult human mesenchymal stem cell activity. Professor Cool returned to the University of Queensland, joining the School of Chemical Engineering in January 2022.

Amanda Kijas
Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Australia

Dr Amanda W. Kijas is a multidisciplinary researcher based at The University of Queensland, leading a new wound healing research program focused on interrogating the underlying science and how we can leverage this to develop innovative new approaches to wound healing products. Repurposing nature’s innovation to instruct better wound healing outcomes from the first stage of bleeding control to driving ordered and timely wound regeneration. With a focus on instructing cellular responses through the biophysical cues that act in synergy with the biochemical microenvironment to modulate these dynamic spatiotemporal cellular responses.

Kendelle Murphy
Garvan Institute of Medical Research, Australia

Dr Kendelle Murphy is a Senior Research Officer in the Cancer Invasion and Metastasis Laboratory at the Garvan Institute of Medical Research. Cancer develops in a complex three-dimensional environment, where tumour cell communication with the surrounding stroma governs cancer cell behaviour. Dr Murphy uses novel state-of-the-art intravital (in vivo, ACRF INCITe Centre) imaging approaches to provide new insights into how cells behave in a physiologically relevant environment, thereby improving our understanding of disease progression, drug delivery and efficacy. Pancreatic Ductal Adenocarcinoma (PDAC) is a highly lethal disease with few treatment options. Multimodal chemotherapy regimens including gemcitabine/Abraxane and FOLFIRINOX are the current standard-of-care in the clinic, however these have limited benefits to extend survival. Focal Adhesion Kinase (FAK) is known to modulate bi-directional communication between the tumour and surrounding ECM driving disease, influencing disease progression, therapy response and the development of pro-tumorigenic fibrosis.
As a CINSW (ECR) Fellow Dr Murphy conducts research has a clear focus on clinical translation. Importantly this research led to the establishment of a Phase II clinical trial (Amplia Therapeutics Ltd, ACCENT Trial, Q3 2022), highlighting the translational and collaborative capacity of her work.

Kylie Sandy-Hodgetts
Centre for Molecular Medicine & Innovative Therapeutics, Murdoch University, Australia

Kylie is Associate Professor, Centre for Molecular Medicine & Innovative Therapeutics, Murdoch University and Honorary Senior Lecturer, School of Medicine, Cardiff University. She is Founder and President of a not-for-profit association, the International Surgical Wound Complications Advisory Panel (ISWCAP). ISWCAP’s vision is to generate awareness of surgical wound complications and improve outcomes for patients through early detection, and prevention via education and research with an international panel of experts. Kylie is a Research Scientist and Chief Investigator of several clinical trials ranging from Phase 1 first in human studies to phase 3-4 comparative effectiveness trials. Kylie’s research focuses upon early identification, prevention and management of surgical wound complications including surgical site infection (SSI) and surgical wound dehiscence (SWD). Kylie has Chaired and co-authored over 5 international clinical consensus documents, first authored over 25 original research papers and chaired the ISWCAP Best Practice Statement on the early identification and prevention of surgical wound complications. She is a reviewer for peer reviewed journals and sits on several journal editorial boards.
She is a Past Chair of the Board of Wounds Australia and has served on several national and international boards including the World Union of Wound Healing Societies (WUWHS) Executive Board as Recorder and the Scientific and Ethics Committee. Kylie Chaired the Australian National Steering Committee Surgical Wounds Panel and Wound Research Directory for the Australian Health Research Alliance National Wound Care Initiative (2020-2023). She was acknowledged internationally for her contribution to the field of surgical site infection prevention as the 2021 Winner of the Journal of Wound Care World Union Innovation in Surgical Site Infection Award.

Fiona Wood
UWA Medical School, University of Western Australia, Australia

Winthrop Professor Fiona Wood University of Western Australia is a Plastic & Reconstructive Surgeon specialising in the field of burn care, trauma, and scar reconstruction. As Director of the WA Burns Service of Western Australia since 1991 she is consultant surgeon at both the South Metropolitan Heath Service, Fiona Stanley Hospital and the Child and Adolescent Health Service, Perth Children’s Hospital. As director of burns injury research unit she leads an interdisciplinary team with broad collaboration focused on translation to improve clinical outcomes. She sits on the national science and technology council and was Australian of the year in 2005.

Khoon Lim
School of Medical Sciences, University of Sydney, Australia

Khoon is a biomedical engineer with specialization in polymer chemistry. He completed a concurrent degree – Bachelors (Hons 1) in Chemical Engineering and Masters in Biomedical Engineering, followed by a PhD in Biomedical Engineering (graduated 2014) from the University of New South Wales. He then went to join the Department of Orthopedic Surgery and Musculoskeletal Medicine at the University of Otago Christchurch in New Zealand for a postdoctoral fellowship, where he established the Light Activated Biomaterials (LAB) research group in 2019. In 2022, he joined the University of Sydney.
His research focus is on adopting a class of polymers known as hydrogels as tissue engineering matrices for a variety of applications. His has developed a number of research technology platforms, primarily using photo-polymerizable hydrogel bioinks for 3D bioprinting of functional tissues and also delivery of bioactive molecules to promote tissue regeneration. He has successfully raised a total of >$8M research grant funding ($6.5M as lead CI). He has been awarded a number of New Zealand’s most prestigious grants and fellowships, including the MARSDEN Fast Start Grant and Rutherford Discovery Fellowship from the Royal Society of New Zealand, as well as the Emerging Researcher First Grant, Sir Charles Hercus Health Research Fellowship and Project Grant from the Health Research Council of New Zealand. Since his move to Australia, he has been successful in attracting funding in a number of prestigious schemes, including the NSW Health Cardiovascular Elite Grant and the Australian Research Council Future Fellowship.

Ferry Melchels
Future Industries Institute, University of South Australia, Australia

Ferry Melchels is the research professor of Biomaterials and Tissue Engineering at the Future Industries Institute at UniSA (Mawson Lakes campus). His main interests lie in polymeric biomaterials for 3D printing, tissue engineering, and drug and vaccine delivery. His work has been published in leading journals, attracting over 16,000 citations. He is a recipient of the Patrick Neill Medal for Early Career Researchers in the Life Sciences from the Royal Society of Edinburgh, and the Mid-Career Investigator Award from the International Society for Biofabrication.
Ferry holds an MSc (2005) in chemical engineering and PhD (2010) in biomaterials from the University of Twente (The Netherlands). He was a Marie Curie post-doctoral fellow between two of the pioneering institutes in Biofabrication; Queensland University of Technology (Brisbane, Australia) and University Medical Center Utrecht (The Netherlands) and held his first PI position at Heriot-Watt University in Edinburgh (UK) from 2015-2023. Besides home brewing the best beers on the weekend, his future aim is to continue advancing materials-based technology platforms for biomedical applications.

Clair Baldock
Professor of Biochemistry at the Manchester Cell-Matrix Centre, University of Manchester, UK

Clair Baldock is a Professor of Biochemistry at the University of Manchester and Group Leader in the Manchester Cell-Matrix Centre. After a PhD in X-ray crystallography at the University of Sheffield, Clair was awarded a Royal Society Study Visit to the University of Auckland to develop further skills in protein biochemistry and molecular biology in Professor Ted Baker’s group. Following this, Clair completed postdoctoral training in the group of Professor Cay Kielty at the University of Manchester and was subsequently awarded a Royal Society Olga Kennard Research Fellowship in 2001 to establish her independent research group with focus on the structure and function of cell-matrix assemblies and complexes, in particular elastic fibre proteins fibrillin and tropoelastin. In 2007, Clair was awarded a tenured position at the University of Manchester where her research group continues to focus on the extracellular regulation of growth factor signalling using a combination of structural, cell biological and biochemical approaches. Recently, her team has determined the structure of fibrillin microfibrils from mammalian tissue using cryo-electron microscopy to reveal the consequence of pathogenic mutations on latent TGFβ binding.

Jennifer Young
Mechanobiology Institute, National University of Singapore, Singapore

Jennifer Young was trained as a biomedical engineer at the University of California, San Diego. During her Ph.D. with Prof. Adam Engler, she studied the role of mechanics in cardiac development, and created a hydrogel system capable of mimicking dynamic tissue properties in vitro. Inspired by the role of extracellular matrix (ECM) in dictating cell behaviour and fate, she joined the Cellular Biophysics group of Prof. Joachim Spatz at the Max Planck Institute for Medical Research (Heidelberg, Germany) to study the contribution of nanoscale ECM cues to cellular function. There, she discovered that variations in nanoscale ligand presentation alone affect chemoresistance in breast cancer cells, which has great implications in cancer treatment strategies. Currently she is at the Mechanobiology Institute and Biomedical Engineering Department at the National University of Singapore where her work focuses on identifying and mimicking micro-to-nanoscale matrix properties and unravelling their contributions to cellular behaviour in a diverse set of biological environments.

Andrew Holle
Mechanobiology Institute, National University of Singapore, Singapore

Andrew Holle received a Bachelor of Science, Engineering (B.S.E) from Arizona State University, where he worked in labs of Dr. Christine Pauken and Dr. Deirdre Meldrum. He then received his Ph.D. at the University of California, San Diego, where he worked in Dr. Adam Engler’s Stem Cell Biology and Bioengineering group. There, he identified the mechanosensitive role of the focal adhesion protein vinculin in substrate stiffness-induced stem cell differentiation. Looking to explore the commonalities between stem cell and cancer mechanobiology, he then joined Prof. Joachim Spatz’s Cellular Biophysics group at the Max Planck Institute for Medical Research (Stuttgart, Germany). There, he used photolithography and microfluidics to build microchannel assays to better characterize cancer cell invasion and migration in confinement. His Confinement Mechanobiology lab at the Mechanobiology Institute and in the NUS Biomedical Engineering department focuses on the role of confinement in mechanobiology, with an emphasis on novel strategies for controlling stem cell differentiation.

Alexander Nyström
Department of Dermatology, Medical Center – University of Freiburg, Freiburg, Germany

Dr Nyström’s main focus is the extracellular matrix and the dermal microenvironment in homeostasis and as initiator and driver of chronic wounds, fibrosis and cancer. To understand the multifaceted roles of the extracellular matrix, its specific components and their deficiencies play in these processes, it is necessary to go beyond the skin. Dr Nyström has an interest in the monogenetic skin blistering disorder dystrophic epidermolysis bullosa (DEB) (caused by deficiency of type VII collagen). People with DEB develop chronic wounds, progressive soft tissue fibrosis and aggressive SCCs at an early age. My group uses the disease as a model to delineate mechanisms for orphan genetic and common acquired disorders. Consequently, part of our research is focused on development of causative and evidence-based symptom-relief therapies for DEB. The aim is that some of these therapies can also be applied to common acquired wound healing pathologies.
Dr Nyström studied biochemistry and molecular biology at Lund University, Sweden and obtained a doctoral degree from the same university for studies on laminins in health and acquired and genetic diseases in the laboratory of the late Dr. Peter Ekblom. After postdoctoral work on proteoglycans in the laboratory of Dr. Renato Iozzo at the Thomas Jefferson University in Philadelphia, following Dr Nyström moved to the laboratory of Dr. Bruckner-Tuderman Freiburg, Germany to focus his research on skin biology. Since 2013 Alexander has his own independent research group at the Department of Dermatology, Medical Center – University of Freiburg, Freiburg Germany.

Claudia Loebel
Assistant Professor of Materials Science & Engineering at the University of Michigan, USA

Claudia Loebel, M.D. Ph.D., is an Assistant Professor of Materials Science & Engineering and a Biological Sciences Scholar at the University of Michigan, US. She obtained her MD (2011) at the Martin-Luther University Halle-Wittenberg in Germany and PhD (2016) at ETH Zurich (Switzerland) and completed a postdoctoral fellowship in the laboratory of Professor Jason Burdick at the University of Pennsylvania. Her research involves the development of metabolic labelling approached and biomaterial platforms to characterize and uncover the role of nascent matrix microenvironments on cell and tissue function. The applications of this research range from guiding lung alveolar stem/progenitor cell fate through material cues to developing engineered platforms for tissue repair and therapeutic treatment. Claudia Loebel is currently serving as an Associate Editor of the Wiley Journal of Biomedical Materials Research Part A (JBMRA). She was awarded the 2023 David and Lucile Packard Foundation Fellowship for her work on cell-matrix interactions, and the Pathway to Independence Award (K99/R00) through the National Heart, Lung, and Blood Institute at NIH and the Innovator Award through the American Lung Association to probe mechanisms of alveolar epithelial cell dysfunction.

Yuval Rinkevich
Director of the Helmholtz Institute of Regenerative Biology and Medicine at the Helmholtz Center, Munich, Germany

Dr. Rinkevich has been working at the cutting edge of our understanding of tissue/organ repair and regeneration for the last 20 years. The scientific focus of the Rinkevich lab lies in identifying principles of tissue/organ repair and regeneration, and developing a knowledge foundation for therapeutic strategies in clinical use. His lab explores the stem cells, cellular lineages and mechanisms by which tissues/organs repair and regenerate following injury.

His passion for healing responses and tissue rejuvenation can be traced throughout his career track, obtaining his PhD degree from the Technion-Israel Institute of Technology, where he studied whole body regeneration from single blood vessels in Protochordates. Dr Rinkevich moved to Stanford University in the US to join the renowned immunology lab of Prof. Irving L. Weissman, where he explored the cellular lineages and stem cells in mammalian tissue repair and regeneration. His work at Stanford projected Dr Rinkevich into the forefront of the tissue repair field for his pioneering work uncovering the role of fibroblast lineages in the transition from scarless to scar forming tissue responses.

Today Dr Rinkevich is the Director of the Helmholtz Institute of Regenerative Biology and Medicine at the Helmholtz Center, Munich, Germany. His lab continues to push forward our understanding of tissue/organ repair and regeneration. His latest work describing the fascia in tissue fibrosis in multiple organ systems is reinventing the way we look at tissue repair and regeneration, opening our minds to a revolution in antifibrotic therapy and the potential to prevent and potentially resolve fibrotic disease.

Hello world.

This is a sample box, with some sample content in it.

TEMTIA X Updates

Enter your details below to learn about the latest developments as we prepare for TEMTIA X in November.